Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Licensing > BSW202203

Anti-GCC humanized antibody

Discovery
Preclinical
IND
PH1
PH2
PH3
BLA Filing
Active
  • Project profile
    Project name: Anti-GCC humanized antibody
    Indications: Solid Tumor
    Research phase: Preclinical
    Cooperation demands: sequence authorization or project transfer
  • Highlights

    1. MoA:


    (1) Guanylate cyclase 2C (GCC) is encoded by GUCY2C gene in human body. The receptor has an extracellular ligand binding domain, a transmembrane region, a region similar to the protein kinase sequence and a c-terminal guanylate cyclase domain. GCC signal pathway can inhibit cell proliferation, protect tight connections between cells, inhibit p53 degradation, promote DNA damage repair, reduce cell cycle progression, and promote oxidative phosphorylation.


    (2) GCC is highly expressed in colorectal cancer, gastric cancer and esophageal cancer, and only in intestinal and colon tissues in normal tissues, but not in other tissues.



    Excellent preclinical results


    2. Excellent preclinical results:


    (1) Compared with Benchmark (PF-07062119), this antibody has better affinity for HEK293T-hGCC cells.


    (2) The binding epitope of the antibody to GCC is different from the natural ligand guanosine protein of GCC.


    (3) The antibody can be rapidly internalized by 293T-hGCC cells.


    (4) GCC-CD3 BsAb can effectively activate Jurkat cells; Activates T-cell-mediated cytotoxic effects.

  • Project Introduction

    1. Asset type: Anti-GCC humanized antibody

    2. Indication: Solid Tumor (Colorectal, gastric and esophageal cancers)

    3. Stage:Preclinical

    4. Cooperation: sequence authorization or project transfer

    5. Research progress:

    (1) Ongoing Preclinical research:
    Anti-GCC humanized antibody has high affinity.
    It is different from the natural GCC ligand binding epitope.
    GCC-CD3 BsAb can activate T cells and T-cell-mediated cytotoxic effects.

Comments (0)

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message